Non-ST-elevation heart attack (NSTEMI)
An NSTEMI is a heart attack in which the ST segment of the electrocardiogram is not raised. The ST finding is often used to decide the treatment protocol, so doctors describe this kind of heart attack and the STEMI kind separately.
Also called NSTEMI · non-ST elevation myocardial infarction · Non-ST Elevated Myocardial Infarction
- Condition
- In this atlas
Overview
Technical summary
MeSH D000072658, last updated 2019-07-01; the definition rests on its scope note, and the note on the ST finding is shared with the STEMI heading. The place under acute coronary syndrome rests on the first sentence of the abstract of one open-access paper (PMC11904130). A US government patient page on heart attack gives the general facts for the parent record; it does not mention ST elevation.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Prasugrel
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 56
Record details
- Record id
cardio:nstemi- Content hash
aef5cc3703709b4524d87d55eee75ca1f08a61ac26bf815ee012851baf6ac09e